 CHICAGO--BUSINESS WIRE-- GvokeHypoPen--Xeris Pharmaceuticals, Inc. Nasdaq: XERS, a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an exclusive distribution agreement with Megapharm Ltd. Megapharm, a leading Israel-based pharmaceutical company, for the commercialization in Israel and the Palestinian Authority of Xeris Gvoke glucagon in 